IMPORTANCE Purpuric skin lesions have only rarely been reported in patients receiving epidermal growth factor receptor inhibitors. However, their clinical and histopathologic presentations have varied considerably.
T he aberrant expression of epidermal growth factor receptor (EGFR) has been demonstrated in many cancers of epithelial origins, 1 especially non-small cell lung cancer. With the increasing use of EGFR tyrosine kinase inhibitors (TKIs) in treating cancers and the high incidence of resulting skin toxic effects, it is important for dermatologists to be familiar with the adverse effects of these drugs. In addition to the common skin toxic effects, 2 some rare effects have also been reported. Previously, a case report 3 described patients with purpuric lesions on the legs with marked xerosis after using EGFR TKIs, and this condition has been termed severe purpuric xerotic dermatitis.Inthe following years, a few reports 4-7 revealed diverse clinical and histopathologic presentations of these purpuric lesions. To better understand and further investigate these purpuric lesions in patients receiving EGFR TKIs, we sought to prospectively identify such patients and then collected their data for evaluation.
Methods
The study was conducted at an integrated dermato-oncologic clinic in a tertiary referral medical center from January 1, 2013 , through December 31, 2015 . All patients provided written informed consent, and data were deidentified. This integrated clinic was established for those patients who developed skin toxic effects after undergoing oncologic treatments. In this setting, we prospectively collected the data of patients who presented with purpuric skin lesions after using EGFR TKIs for their non-small cell lung cancer. Each patient underwent a skin biopsy for histopathologic examinations and tissue cultures. Immunohistochemical staining of filaggrin (rabbit polyclonal antifilaggrin IgG, antibody 24584, 1:50; Abcam) and human β-defensin 2 (HBD-2) (rabbit polyclonal anti-HBD-2, antibody 63982, 1:200; Abcam) was also performed. The study was approved by the Research Ethics Committee of the National Taiwan University Hospital. Statistical comparisons between the groups were conducted using single-factor analysis of variance for numerical data and χ 2 tests for categorical data. Statistical significance was defined as 2-sided P < .01.
Results
During the study period, 3350 patients receiving EGFR TKIs had visited the clinic. Among them, 32 patients who presented with purpuric drug eruptions (PDEs) after receiving EGFR TKIs were identified ( female and 6 male). The durations from the first intake of the EGFR TKI to the development of PDEs varied widely, but the median duration was 3.5 months. Clinically, purpuric macules or papules with confluent plaques were predominantly present on the lower extremities in all patients (Figure, A) . In 6 patients (19%), the confluent plaques were arranged in an annular configuration (Figure, B) . Nonfollicular pustules in various sizes were clearly identified in 18 patients (56%) (Figure, C) . In addition, 13 patients (41%) had marked xerotic changes at their lesions that mimicked those seen in eczema craquelé ( Figure, D) . Six patients (19%) had leg edema. Demographic characteristics among the patients with PDEs with and without pustules were similar ( Table 1 and Table 2 ). Fifteen patients (47%) had ever developed acneiform eruptions in the earlier period of EGFR TKI treatment. None of the patients received doxycycline or minocycline hydrochloride preventatively, and no one received warfarin sodium and heparin sodium during the investigation period. The most significant difference was that Staphylococcus aureus was identified in all the patients with the pustules, whereas only 2 patients (14%) without pustules had positive results for S aureus (P < .001). Systemic first-generation cephalosporin antibiotics were initially administrated to all patients for at least 1 week. All patients responded well to the treatment with residual erythema or hyperpigmentation. The dosages of the EGFR TKIs were adjusted for 14 patients (44%) based on the judgments of their oncologists. Among these 14 patients, 3 patients reduced dosages, whereas the other 11 patients ceased use and resumed using the EGFR TKIs after improvement of their cutaneous lesions. Of these 11 patients, all but 1 tolerated the resumption of their EGFR TKI treatment very well without recurrence of the lesions during the follow-up period.
The histopathologic analysis of the PDEs revealed some characteristic features, including epidermal dysmaturation, neutrophil aggregation, red blood cell extravasation, and endothelium plumping (eFigure 1 in the Supplement). Obvious microscopic pustules were predominantly seen in those patients with cutaneous pustules (14 [78%] vs 3 [21%]; P = .002). Of note, frank leukocytoclastic vasculitis was identified in only 3 patients (9%). Six of the 21 patients evaluated by direct immunofluorescence study exhibited few cytoid bodies of IgG or IgM or C3 at the dermoepidermal junction or fibrinogen depositions on the vessels of upper dermis. The expressions of epidermal filaggrin and HBD-2 were reduced in all patients with PDEs compared with healthy control individuals (eFigure 2 in the Supplement).
Discussion
The purpuric change in PDEs might result from the distribution of EGFR on endothelial cells and perivascular smooth muscles. 8 The blockage of the EGFR signaling pathway may lead to inflammation of endothelium, reduced vascular tones, and subsequently increased permeability.
Key Points
Question What are the presentations of purpuric skin lesions attributable to epidermal growth factor inhibitors?
Finding In this study of 32 patients, purpuric drug eruptions were found to be characterized by purpuric papules, pustules, or confluent plaques on the lower extremities but could extend to the trunk and arms. The high rate of bacterial pathogens may be the result of the reduced epidermal expressions of filaggrin and human β-defensin 2.
Meaning Accurate identification with prompt administration of systemic antibiotics provides improvement and resolution of these cutaneous lesions.
A high yield rate of lesional tissue cultures for bacteria highlights the importance of pathogens in PDEs. Among these pathogens, S aureus is the most important one. These pathogens may aggravate tissue inflammation, recruit neutrophils, and then promote the formation of pustules. The improvement or clearance after receiving systemic antibiotics further supports the importance of these pathogens. The integrity of the skin barrier and the function of innate immunity are important for protecting a patient from the invasion of pathogens. The inhibition of the EGFR signaling pathway, however, reduces expressions of the major structure proteins 9 and antimicrobial peptides, 10 leading to a high vulnerability to pathogens in these patients. 11 These findings have also been reported in previous studies. 12,13 Furthermore, aggravated inflammation caused by these pathogens might further dampen epidermal differentiation and thus cause markedly reduced expressions of major components of cornified cell envelopes, resulting in the formation of eczema craquelé-like features. Purpuric drug eruptions, especially those with pustules, should be distinguished from acneiform eruptions, which are frequently encountered in patients receiving EGFR TKIs. Compared with the lesions of acneiform eruptions, 14 lesions of PDEs more frequently have a nonfollicular distribution, a predominant location on the legs, a longer duration to development, and a higher rate of presence of bacterial pathogens. These differences Abbreviations: CoNS, coagulase-negative Staphylococcus; EC, eczema craquelé-like features; EGFR, epidermal growth factor receptor; H, hold use; IV, intravenous; K, keep use; NA, not applicable; PO, oral; R, reduce dosage; TKIs, tyrosine kinase inhibitors; WBC, white blood cell; +, positive; −, negative.
SI conversion factors:
To convert neutrophils to proportion of 1.0, multiply by 0.01; platelets to ×10 9 /L, multiply by 1.0; and WBCs to ×10 9 /L, multiply by 0.001. a These patients had died. The follow-up durations of these patients were calculated from enrollment to their death.
distinguish PDEs from acneiform eruptions and further support the different treatment strategies for these 2 conditions. A previous report 15 described 4 patients who presented with a late form of acneiform eruptions induced by EGFR TKIs. These 4 cases were characterized by delayed onset (several months after start of EGFR TKI treatment), localization on the limbs, S aureus superinfection, and histologically, neutrophils infiltrating predominantly in the follicles without vessel wall damage or leukocytoclasia. All 4 of these patients improved after antibiotic treatment, and 2 of the patients had EGFR TKI dosages reduced. The authors termed this presentation late acneiform toxicity of EGFR inhibitors (LATE syndrome). Compared with the lesions in LATE syndrome, those in PDE exhibit confluent plaques in addition to papules and pustules in a predominant nonfollicular distribution and have histologic evidence of some extent of vessel wall damage. However, some similarities exist between patients with LATE syndrome and those with PDEs, leading us to assume that these 2 conditions might belong to a spectrum of a single disease.
Limitations
The limitation of this study was that it was observational and included only a small number of the patients.
Conclusions
The present study reports an uncommon cutaneous adverse reaction caused by EGFR TKIs. Treatment with systemic antibiotics usually results in improvement. Additional studies are needed to explore the details of the pathomechanisms of PDEs. Filaggrin could be identified in healthy control (A), but its expression is markedly reduced in patients with purpuric drug eruptions (B, C). Similarly, HBD-2 could be well-identified in healthy control (D), but its expression was weak in patients presenting purpuric drug eruptions without pustules (E) and those with pustules (F). All panels used IHC stains with AEC in 200X.
